Lyell's product candidates are enhanced with novel technology designed to generate T cells that resist exhaustion and have qualities of durable stemness in order to drive durable tumor cytotoxicity and achieve consistent and long-lasting clinical response. The company's lead clinical program, LYL314, is a next-generation autologous dual-targeting CD19/CD20 CAR T-cell product candidate under evaluation in a pivotal trial enrolling patients with relapsed and/or refractory large B-cell lymphoma.
Cyborg Score Rationale
Lyell is a clinical-stage company with promising CAR-T technology and recent acquisition of ImmPACT strengthening its pipeline, but faces execution risks inherent to developmental biotechs. Limited revenue ($61K in 2024) and burn rate, combined with cash runway to 2027, create typical biotech risk-reward profile. Lead program advancement provides validation.
Top Insights
Lead program LYL314 advancing through pivotal development for large B-cell lymphoma with positive Phase 1/2 data
Strategic acquisition of ImmPACT Bio strengthened pipeline with dual-targeting CD19/CD20 CAR T-cell candidate
Focus on solid tumors represents massive unmet need (~90% of cancers) where cell therapy remains underdeveloped
Strong cash position of approximately $460M provides runway through multiple clinical milestones into 2027
Named Competitors
CAR-T Therapies — CAR-T cell therapy developer for hematologic and solid tumors
CAR-T Therapies — Engineered T-cell therapy platform for cancer
TIL Therapies — Tumor-infiltrating lymphocyte cell therapy